Home » Stocks » SNGX

Soligenix, Inc. (SNGX)

Stock Price: $0.975 USD -0.055 (-5.34%)
Updated May 11, 2021 10:22 AM EDT - Market open
Market Cap 40.97M
Revenue (ttm) 2.36M
Net Income (ttm) -17.69M
Shares Out 27.49M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $0.975
Previous Close $1.030
Change ($) -0.055
Change (%) -5.34%
Day's Open 0.980
Day's Range 0.951 - 1.020
Day's Volume 569,627
52-Week Range 0.951 - 2.990

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Soligenix Inc (NASDAQ: SNGX) shares dropped during premarket after the company said it would not pursue a rolling marketing application submission for HyBryte (SGX301). Instead, it plans to submit the N...

1 day ago - Benzinga

PRINCETON, N.J., May 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

1 day ago - PRNewsWire

PRINCETON, N.J., May 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...

1 week ago - PRNewsWire

PRINCETON, N.J., April 28, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

1 week ago - PRNewsWire

PRINCETON, N.J., April 26, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

2 weeks ago - PRNewsWire

PRINCETON, N.J., April 13, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

4 weeks ago - PRNewsWire

PRINCETON, N.J., April 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

1 month ago - PRNewsWire

PRINCETON, N.J., March 30, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 16, 2021) - PCG Digital -- The future is looking bright at Soligenix, Inc. In a corporate update released on February 24th, Dr. Christopher Schaber, Chairman,...

1 month ago - Newsfile Corp

PRINCETON, N.J., March 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

2 months ago - PRNewsWire

Soligenix Inc (NASDAQ: SNGX) rises sharply in premarket trading after the publication of positive results from pre-clinical immunogenicity studies for the COVID-19 vaccine candidate, dubbed as CiVax. Th...

2 months ago - Benzinga

New York, New York--(Newsfile Corp. - February 23, 2021) - PCG Digital -- Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix (NASDAQ: SN...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization...

3 months ago - Newsfile Corp

PRINCETON, N.J., Feb. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

3 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - January 25, 2021) - PCG Digital: Advancing health care innovation is a cornerstone of thorough public health policy. Researching and developing new treatments for u...

3 months ago - Newsfile Corp

PRINCETON, N.J., Jan. 19, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

3 months ago - PRNewsWire

PRINCETON, N.J., Jan. 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

4 months ago - PRNewsWire

PRINCETON, N.J., Dec. 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

4 months ago - PRNewsWire

PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

4 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - December 9, 2020) -  The COVID-19 pandemic has been one of the most significant "black swan" events in recent history. As of early December 2020, around 1.5 million...

5 months ago - Newsfile Corp

PRINCETON, N.J., Nov. 12, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

5 months ago - PRNewsWire

PRINCETON, N.J., Nov. 10, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

6 months ago - PRNewsWire

Positive Phase 3 data reported on Oct. 22, solidifies the approvability of SGX301 for CTCL treatment, an estimated $250M annual revenue opportunity, yet SNGX's valuation is only ~$55M. SGX942 for oral m...

6 months ago - Seeking Alpha

PRINCETON, N.J., Oct. 8, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

7 months ago - PRNewsWire

PRINCETON, N.J., Sept. 15, 2020 /PRNewswire/ -- Soligenix, Inc.

7 months ago - PRNewsWire

PRINCETON, N.J., Sept. 10, 2020 /PRNewswire/ -- Soligenix, Inc.

8 months ago - PRNewsWire

PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc.

8 months ago - PRNewsWire

PRINCETON, N.J., Aug. 27, 2020 /PRNewswire/ -- Soligenix, Inc.

8 months ago - PRNewsWire

PRINCETON, N.J., Aug. 14, 2020 /PRNewswire/ -- Soligenix, Inc.

8 months ago - PRNewsWire

Soligenix: Multiple Shots On Goal, Strong Evidence Of Success, And Attractive Valuation

9 months ago - Seeking Alpha

PRINCETON, N.J., July 20, 2020 /PRNewswire/ -- Soligenix, Inc.

9 months ago - PRNewsWire

Soligenix (NASDAQ: SNGX) shares were trading higher on Friday after the company completed enrollment in its Phase 3 clinical trial of SGX942 for the treatment of oral mucositis.

10 months ago - Benzinga

PRINCETON, N.J., June 22, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

10 months ago - PRNewsWire

PRINCETON, N.J., June 9, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

11 months ago - PRNewsWire

PRINCETON, N.J., May 15, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to trea...

11 months ago - PRNewsWire

Soligenix's Upcoming Catalyst For Pipeline Product SGX301 Could Offer A Nice Trade Opportunity

1 year ago - Seeking Alpha

Shares of rare disease biopharma Soligenix, Inc. (NASDAQ: SNGX) were spiking higher Thursday after the company announced a coronavirus-related licensing agreement.

1 year ago - Benzinga

Soligenix: Two Phase-3 Clinical Trials - Results By June 2020

1 year ago - Seeking Alpha

Soligenix is a small biotech company with just ~$20M market cap.

1 year ago - Seeking Alpha

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial to treat oral mucositis in head and neck cancer. This se... [Read more...]

Industry
Biotechnology
IPO Date
Jun 15, 1987
CEO
Christopher Schaber
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
SNGX
Full Company Profile

Financial Performance

In 2020, Soligenix's revenue was $2.36 million, a decrease of -49.04% compared to the previous year's $4.63 million. Losses were -$17.69 million, 89.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Soligenix stock is "Buy." The 12-month stock price forecast is 4.06, which is an increase of 316.41% from the latest price.

Price Target
$4.06
(316.41% upside)
Analyst Consensus: Buy